Research Triangle Park, NC, May 20, 2019 — T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959 (the “Company”), a new orally administered treatment for Alzheimer’s disease (AD), announced today that it has received a grant expected to total $9 million dollars over four years from the National Institute on Aging (NIA), part of NIH, to help fund a Phase 2 clinical study of T3D-959, a novel, metabolic-focused AD drug treatment.
Recent Posts
- T3D Therapeutics Selected to Present Topline Results from the Phase 2 PIONEER Study of T3D-959 as Late Breaking News at the 16th Clinical Trials on Alzheimer’s Disease Conference (CTAD)
- T3D Therapeutics, Inc.: T3D Therapeutics Announces First Patient Dosed in its Phase 2 Study of T3D-959 for the Treatment of Mild to Moderate Alzheimer’s Disease
- T3D Therapeutics Receives a Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program
- Alzheimer’s Association Part The Cloud Grant Program Invests $24 Million in 16 Innovative Research Trials
- Leading Alzheimer’s Disease Experts Join T3D Therapeutics’ Scientific Advisory Board